Alfa Cytology Advances Animal Models for Cancer Research and Humanized Immune System Mouse Models

Alfa Cytology provides in vivo research support for tumor studies and immunotherapy using cancer animal models and humanized immune system mice.

NEW YORK, NY, March 31, 2026 /24-7PressRelease/ — To advance cancer research and the development of new therapeutic strategies, Alfa Cytology has launched an in vivo cancer model development service that integrates an animal model for cancer research and a humanized immune system mouse model platform to enable in vivo studies of tumor mechanisms and drug efficacy evaluation. In oncology drug development, many candidate therapies perform well in the laboratory but fail to achieve the desired efficacy in clinical trials. Therefore, animal models that more closely mimic human physiology are becoming important tools to bridge basic research and clinical translation.

Different types of animal models for cancer research can support diverse research needs. For example, xenograft models and patient-derived xenograft models (PDX models) are often used to evaluate the efficacy of anticancer drugs, while syngeneic models and genetically engineered mouse models are useful for studying the interaction between tumors and the immune system. These models provide important tools for researchers to systematically analyze tumor biological processes and optimize treatment strategies.

With the development of immunotherapy such as immune checkpoint inhibitors and cell therapy, tumor research has gradually focused on the dynamic relationship between tumors and the immune system. However, the traditional mouse model has limitations in immune research, because the mouse immune system is significantly different from the human immune system. To address this problem, humanized immune system mouse models supported by the Hu-Immune™ platform were developed. These models reconstruct a human-like immune system by implanting human immune cells or hematopoietic stem cells into immunodeficient mice, enabling researchers to more realistically study tumor immune responses and immunotherapy mechanisms.

Relying on relevant research resources, Alfa Cytology has cooperated with research institutions to carry out the study of the humanized immune system mouse model, so as to provide experimental support for tumor immunology research and immunotherapy evaluation. By incorporating the humanized immune system mouse model technology, the research team was able to study the interaction between the human immune system and tumors in vivo and more fully evaluate the potential effects of novel immunotherapies.

“In cancer research, reliable in vivo models are essential to assess the feasibility of therapeutic strategies,” said a spokesperson from Alfa Cytology. “By integrating animal models for cancer research with humanized immune system mouse models, we aim to provide a systematic research platform that helps advance basic cancer research and the development of new therapies.”

About Alfa Cytology
Alfa Cytology is focused on providing preclinical research support for cancer research, with a focus on cancer immunotherapy and innovative anti-cancer strategies. By integrating advanced experimental techniques, animal model resources and professional research teams, Alfa Cytology provides experimental platforms and technical support for a variety of emerging anti-tumor technologies to help scientific research teams promote the process of preclinical research.

—
For the original version of this press release, please visit 24-7PressRelease.com here